Promising Treatment for Primary Immunodeficiency
Takeda has announced positive topline results from its pivotal Phase 2/3 clinical trial of TAK-881 in patients with Primary Immunodeficiency Disease (PID), conducted in Osaka, Japan and Cambridge, Massachusetts.
The trial demonstrated pharmacokinetic comparability between TAK-881 and the established treatment HYQVIA, while also reducing infusion volume and duration for PID patients. This investigational treatment, TAK-881, is an Immune Globulin Subcutaneous (Human) 20% Solution facilitated with Recombinant Human Hyaluronidase.
The TAK-881-3001 clinical trial evaluated the PK, efficacy, safety, tolerability, and immunogenicity of TAK-881 in both adults and pediatric patients aged 2 years and older. The trial showed that TAK-881 maintained protective IgG levels and had a comparable safety profile to HYQVIA, with no new safety signals observed.
Kristina Allikmets, MD, PhD, Senior Vice President and Head of Plasma Derived Therapies R&D at Takeda, stated, "These Phase 2/3 results showed the pharmacokinetic profile of TAK-881 was comparable to HYQVIA, an established IG standard of care in patients with PID, while offering the potential advantages of fewer injection sites, a flexible treatment schedule and shorter infusion times."
Initial topline data revealed that TAK-881 achieved a geometric mean ratio of 99.67% for IgG exposure compared to HYQVIA, showcasing its effectiveness. Patients receiving TAK-881 benefited from half the infusion volume required by HYQVIA, experiencing reduced infusion durations.
Comparable Safety and Efficacy
TAK-881 provides immune protection with infection rates comparable to HYQVIA, as shown by consistently maintained protective IgG levels during the study. The safety and tolerability profiles of TAK-881 are similar to those of HYQVIA, ensuring no new safety signals were observed.
Richard L. Wasserman, MD, PhD, allergist/immunologist and principal investigator for the trial, remarked, "These topline results from TAK-881-3001 are encouraging. They show that a highly concentrated, hyaluronidase-facilitated subcutaneous IG can provide immune protection with a more manageable infusion experience intended to enhance the day-to-day lives of patients living with PID."
The ongoing TAK-881-3002 study will further evaluate the long-term safety and tolerability of TAK-881 in PID patients. Takeda plans to submit regulatory applications in the United States, European Union, and Japan in the fiscal year 2026. This reflects their broader commitment to advancing next-generation IG therapies.
